Caplin Point Laboratories Ltd
NSE:CAPLIPOINT
Operating Margin
Caplin Point Laboratories Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| IN |
|
Caplin Point Laboratories Ltd
NSE:CAPLIPOINT
|
166.7B INR |
30%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
675.7B USD |
40%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
368.1B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
48%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
206.6B CHF |
33%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
180.8B CHF |
33%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
161.8B GBP |
24%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
195.5B USD |
34%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
11%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
115.5B EUR |
22%
|
Caplin Point Laboratories Ltd
Glance View
Nestled in the bustling business corridors of Chennai, Caplin Point Laboratories Ltd. emerged quietly yet resolutely from its humble origins in 1990. With foresight and strategic maneuvering, the company embarked on a global journey, primarily serving markets across the African, Latin American, and Southeast Asian regions. The firm specializes in a wide array of pharmaceutical products, encompassing everything from injectables and ophthalmics to oral solids and liquids. By focusing on markets that were often overlooked by larger pharmaceutical giants, Caplin Point carved out a niche that allowed it to flourish with minimal competition. The company's business model hinges on leveraging cost-effective manufacturing paired with a deep understanding of diverse regulatory environments, deftly navigating these to establish a loyal customer base amidst underrepresented geographies. The revenue streams of Caplin Point Laboratories are primarily fueled by its ability to adapt product lines to meet the specific needs of each market it serves. This adaptability, combined with a robust distribution network, facilitates the swift movement of goods—ensuring prompt delivery to consumers who rely on its products for basic health needs. Through strategic partnerships and continual investment in research and development, Caplin Point enhances its capacity for innovation, allowing it to advance the quality and range of its pharmaceutical offerings. Furthermore, the company has steadily expanded into regulated markets with its sights set on injectables and has plans for further diversification. This strategic orientation underscores its ambition to transition from a regional powerhouse to a formidable player on the broader global stage.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Caplin Point Laboratories Ltd's most recent financial statements, the company has Operating Margin of 29.6%.
You don't have any saved screeners yet